Silymarol tab p/o 70 mg in bl in pack No. 15×2

Name:
Silimarol.
Description:
Round, biconvex tablets with a diameter of 8.5 – 9.5 mm, a thickness of 5.3 – 5.8 mm and a weight of 0.32 – 0.36 g, coated with a white-gray color, light brownish-yellow at the break. The main active ingredient is Silibinin. Release form Tablets. Dosage 70 ml. Pharmacological action Drugs for the treatment of liver diseases. The active ingredient of the drug is silymarin, obtained from the extract of milk thistle fruits. A standardized extract contains 70 to 80% silymarin. Indications for use Recommended for toxic liver damage, as a supportive treatment for chronic inflammatory liver diseases. The protective effect of silymarin on the liver is explained by the stabilization of cell membranes that protect against the damaging effects of toxic substances. The proposed mechanism of action, in addition to protecting the cell membranes of hepatocytes, is the intensification of cellular processes of protein synthesis, leading to faster regeneration, and the ability to form new cells, as well as antioxidant activity. Dosage and administration Unless otherwise indicated, adults and children over 12 years of age are advised to take 1 tablet 3 times a day. In case of severe liver damage, after consulting a doctor, you can increase the dose to 5 tablets per day. The duration of the course of treatment is determined by the doctor individually, depending on the nature and characteristics of the course of the disease. Usually the duration of treatment is at least 4 weeks. In the case of the use of the drug Silymarol 70 mg at a dose greater than prescribed Signs or symptoms of overdose or poisoning have not yet been registered. The undesirable effects described above may be exacerbated. No specific antidote is known. If necessary, symptomatic measures are recommended. If a dose of Silimarol 70 mg is missed, it is possible to safely return to the previous treatment regimen. Do not use a double dose to make up for a missed one. Use during pregnancy and lactation Pregnancy Due to the lack of data confirming the safety of use, it is not recommended to use the drug during pregnancy. Breast-feeding Due to the lack of data confirming the safety of use, it is not recommended to use the drug during breast-feeding. Precautions If you experience symptoms of jaundice (jaundice of the skin, yellowness of the sclera), you should consult your doctor. It is not recommended to use the drug for acute poisoning. Both during and after treatment, the use of hepatotoxic agents should be avoided. Because of the possible estrogen-like effect of silymarin, it should be used with caution in patients with hormonal disorders (endometriosis, uterine fibroids, breast, ovarian and uterine carcinoma, prostate carcinoma). Due to the content of glucose and sucrose, the drug should not be used in patients with rare hereditary forms of fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency. If the patient has an intolerance to some sugars, a doctor should be consulted before taking this drug. Interaction with other drugs In the case of the use of silymarin at the highest possible doses simultaneously with oral contraceptives or drugs for estrogen replacement therapy, the effectiveness of the latter may decrease. Due to the influence of silymarin on the cytochrome P450 system, there is a possibility of enhancing the effect of drugs such as diazepam, alprazolam, ketoconazole, lovastatin, atorvastatin, vinblastine. Composition 1 tablet contains: Active ingredient: 100 mg dry milk thistle fruit extract (Silybi mariani fructus extractum DER 20 – 34: 1, extractant: methanol 90%, excipient – sodium benzoate < 0.2%), which corresponds to 70 mg of flavolignans in terms of to silybin. Excipients: glucose, potato starch, sucrose, talc, magnesium stearate, gum arabic (gum arabic), a mixture of white beeswax and carnauba wax (Capol® 1295). Release form: 2 blisters of aluminum foil and PVC film (A1./PVC) of 15 tablets, in a carton box. Side effect Criteria for assessing the frequency of adverse drug reactions: very often (≥ 1/10), often (≥ 1/100, < 1/10), infrequently (≥ 1/1000, < 1/100), rarely (≥ 1/10 10,000, < 1/1000), very rare (< 1/10,000). In rare cases, the following side effects can be observed: From the digestive tract: nausea, vomiting, dyspepsia, mild diarrhea; From the respiratory system: shortness of breath; From the urinary system: increased diuresis; From the immune system: very rarely, hypersensitivity reactions are possible, including skin rashes, itching; with an unknown frequency of anaphylactic shock. It is very rare to observe an increase in existing vestibular disorders. Storage conditions 3 years. Buy Silimarol tab po 70 mg in bl in pack No. 15x2 Price for Silimarol tab po 70 mg in bl in pack No. 15x2